1. Introduction {#sec1-jcm-08-00372}
===============

Acute kidney injury (AKI) is associated with high mortality worldwide (1.7 million deaths per year) \[[@B1-jcm-08-00372],[@B2-jcm-08-00372],[@B3-jcm-08-00372],[@B4-jcm-08-00372]\]. Patients who survive AKI are at increased risk for significant morbidities such as hypertension and progressive chronic kidney disease (CKD) \[[@B5-jcm-08-00372]\]. The incidence of AKI has steadily increased in recent years \[[@B2-jcm-08-00372]\]. It has been suggested that AKI's global burden is 13.3 million cases a year \[[@B6-jcm-08-00372]\]. In the United States, hospitalizations for AKI have been steeply rising, and data from national inpatient sample shows that the number of hospitalizations due to AKI increased from 953,926 in 2000 to 1,823,054 in 2006 and 3,959,560 in 2014, which accounts for one hospitalization associated with AKI every 7.5 minutes \[[@B7-jcm-08-00372],[@B8-jcm-08-00372]\].

AKI is a common and significant complication after liver transplantation (LTx), and is associated with increased mortality, hospital length of stay, utilization of resources, and health care costs \[[@B9-jcm-08-00372],[@B10-jcm-08-00372],[@B11-jcm-08-00372],[@B12-jcm-08-00372],[@B13-jcm-08-00372],[@B14-jcm-08-00372],[@B15-jcm-08-00372],[@B16-jcm-08-00372],[@B17-jcm-08-00372],[@B18-jcm-08-00372],[@B19-jcm-08-00372],[@B20-jcm-08-00372],[@B21-jcm-08-00372],[@B22-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B26-jcm-08-00372],[@B27-jcm-08-00372]\]. Although the survival of LTx recipients has improved substantially over the past five decades, mortality rates related to post-LTx AKI and subsequent progressive CKD remain high and are of increasing concern \[[@B14-jcm-08-00372],[@B15-jcm-08-00372],[@B28-jcm-08-00372],[@B29-jcm-08-00372],[@B30-jcm-08-00372],[@B31-jcm-08-00372]\]. The underlying mechanisms for post-LTx AKI appear to be complex and differ from other medical or surgery-associated AKI \[[@B11-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372]\]. Recent studies have suggested several important factors that influence post-LTx AKI, including hepatic ischemia-reperfusion injury (HIRI) \[[@B36-jcm-08-00372],[@B37-jcm-08-00372],[@B38-jcm-08-00372]\], increased use of high-risk or marginal grafts, and transplantation of liver grafts to sicker patients with higher Model For End-Stage Liver Disease (MELD) score or with more comorbidities \[[@B23-jcm-08-00372],[@B39-jcm-08-00372],[@B40-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B45-jcm-08-00372],[@B46-jcm-08-00372],[@B47-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B50-jcm-08-00372],[@B51-jcm-08-00372]\]. In our literature review, the reported incidences are a farrago, having a range between 5% to 94% \[[@B10-jcm-08-00372],[@B11-jcm-08-00372],[@B14-jcm-08-00372],[@B15-jcm-08-00372],[@B16-jcm-08-00372],[@B17-jcm-08-00372],[@B18-jcm-08-00372],[@B19-jcm-08-00372],[@B20-jcm-08-00372],[@B21-jcm-08-00372],[@B22-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B28-jcm-08-00372],[@B29-jcm-08-00372],[@B30-jcm-08-00372],[@B31-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372],[@B39-jcm-08-00372],[@B40-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B45-jcm-08-00372],[@B46-jcm-08-00372],[@B47-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B52-jcm-08-00372],[@B53-jcm-08-00372],[@B54-jcm-08-00372],[@B55-jcm-08-00372],[@B56-jcm-08-00372],[@B57-jcm-08-00372],[@B58-jcm-08-00372],[@B59-jcm-08-00372],[@B60-jcm-08-00372],[@B61-jcm-08-00372],[@B62-jcm-08-00372],[@B63-jcm-08-00372],[@B64-jcm-08-00372],[@B65-jcm-08-00372],[@B66-jcm-08-00372],[@B67-jcm-08-00372],[@B68-jcm-08-00372],[@B69-jcm-08-00372],[@B70-jcm-08-00372],[@B71-jcm-08-00372],[@B72-jcm-08-00372],[@B73-jcm-08-00372],[@B74-jcm-08-00372],[@B75-jcm-08-00372],[@B76-jcm-08-00372],[@B77-jcm-08-00372],[@B78-jcm-08-00372],[@B79-jcm-08-00372],[@B80-jcm-08-00372]\]. These wide variabilities are possibly due to non-uniform definitions of AKI \[[@B10-jcm-08-00372],[@B11-jcm-08-00372],[@B14-jcm-08-00372],[@B15-jcm-08-00372],[@B16-jcm-08-00372],[@B17-jcm-08-00372],[@B18-jcm-08-00372],[@B19-jcm-08-00372],[@B20-jcm-08-00372],[@B21-jcm-08-00372],[@B22-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B28-jcm-08-00372],[@B29-jcm-08-00372],[@B30-jcm-08-00372],[@B31-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372],[@B39-jcm-08-00372],[@B40-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B45-jcm-08-00372],[@B46-jcm-08-00372],[@B47-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B52-jcm-08-00372],[@B53-jcm-08-00372],[@B54-jcm-08-00372],[@B55-jcm-08-00372],[@B56-jcm-08-00372],[@B57-jcm-08-00372],[@B58-jcm-08-00372],[@B59-jcm-08-00372],[@B60-jcm-08-00372],[@B61-jcm-08-00372],[@B62-jcm-08-00372],[@B63-jcm-08-00372],[@B64-jcm-08-00372],[@B65-jcm-08-00372],[@B66-jcm-08-00372],[@B67-jcm-08-00372],[@B68-jcm-08-00372],[@B69-jcm-08-00372],[@B70-jcm-08-00372],[@B71-jcm-08-00372],[@B72-jcm-08-00372],[@B73-jcm-08-00372],[@B74-jcm-08-00372],[@B75-jcm-08-00372],[@B76-jcm-08-00372],[@B77-jcm-08-00372],[@B78-jcm-08-00372],[@B79-jcm-08-00372],[@B80-jcm-08-00372]\]. In addition, despite progress in transplant medicine, the incidence, risk factors, and mortality associated with AKI in post-LTx patients and their trends remain unclear \[[@B10-jcm-08-00372],[@B11-jcm-08-00372],[@B14-jcm-08-00372],[@B15-jcm-08-00372],[@B16-jcm-08-00372],[@B17-jcm-08-00372],[@B18-jcm-08-00372],[@B19-jcm-08-00372],[@B20-jcm-08-00372],[@B21-jcm-08-00372],[@B22-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B28-jcm-08-00372],[@B29-jcm-08-00372],[@B30-jcm-08-00372],[@B31-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372],[@B39-jcm-08-00372],[@B40-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B45-jcm-08-00372],[@B46-jcm-08-00372],[@B47-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B52-jcm-08-00372],[@B53-jcm-08-00372],[@B54-jcm-08-00372],[@B55-jcm-08-00372],[@B56-jcm-08-00372],[@B57-jcm-08-00372],[@B58-jcm-08-00372],[@B59-jcm-08-00372],[@B60-jcm-08-00372],[@B61-jcm-08-00372],[@B62-jcm-08-00372],[@B63-jcm-08-00372],[@B64-jcm-08-00372],[@B65-jcm-08-00372],[@B66-jcm-08-00372],[@B67-jcm-08-00372],[@B68-jcm-08-00372],[@B69-jcm-08-00372],[@B70-jcm-08-00372],[@B71-jcm-08-00372],[@B72-jcm-08-00372],[@B73-jcm-08-00372],[@B74-jcm-08-00372],[@B75-jcm-08-00372],[@B76-jcm-08-00372],[@B77-jcm-08-00372],[@B78-jcm-08-00372],[@B79-jcm-08-00372],[@B80-jcm-08-00372],[@B81-jcm-08-00372],[@B82-jcm-08-00372],[@B83-jcm-08-00372]\].

Thus, we performed a systematic review to summarize the incidence (using standard AKI definitions of Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE), Acute Kidney Injury Network (AKIN), and Kidney Disease: Improving Global Outcomes (KDIGO) classifications), risk factors, and mortality and their trends for AKI in patients undergoing LTx.

2. Methods {#sec2-jcm-08-00372}
==========

2.1. Search Strategy and Literature Review {#sec2dot1-jcm-08-00372}
------------------------------------------

The protocol for this systematic review was registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018100664). A systematic literature search of MEDLINE (1946 to December 2018), EMBASE (1988 to December 2018) and the Cochrane Database of Systematic Reviews (database inception to December 2018) was performed to evaluate the incidence of AKI in adult patients undergoing LTx. The systematic literature review was conducted independently by two investigators (C.T. and W.C.) using the search strategy that consolidated the terms "acute kidney injury" OR "renal failure" AND "liver transplantation,\" which is provided in online [supplementary data 1](#app1-jcm-08-00372){ref-type="app"}. No language limitation was implemented. A manual search for conceivably related studies using references of the included articles was also performed. This study was conducted by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement \[[@B84-jcm-08-00372]\] and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) \[[@B85-jcm-08-00372]\].

2.2. Selection Criteria {#sec2dot2-jcm-08-00372}
-----------------------

Eligible studies must be clinical trials or observational studies (cohort, case-control, or cross-sectional studies) that reported the incidence of post-LTx AKI in adult patients (age \>/= 18 years old). Included studies must provide data to estimate the incidence of post-LTx AKI with 95% confidence intervals (CI). Retrieved articles were individually reviewed for eligibility by the two investigators (C.T. and W.C.). Discrepancies were addressed and solved by mutual consensus. Inclusion was not limited by the size of study.

2.3. Data Abstraction {#sec2dot3-jcm-08-00372}
---------------------

A structured data collecting form was used to obtain the following information from each study, including title, name of the first author, year of the study, publication year, country where the study was conducted, post-LTx AKI definition, incidence of AKI post-LTx, risk factors for post-LTx AKI, and impact of post-LTx AKI on patient outcomes.

2.4. Statistical Analysis {#sec2dot4-jcm-08-00372}
-------------------------

Analyses were performed utilizing the Comprehensive Meta-Analysis 3.3 software (Biostat Inc, Englewood, NJ, USA). Adjusted point estimates from each study were consolidated by the generic inverse variance approach of DerSimonian and Laird, which designated the weight of each study based on its variance \[[@B86-jcm-08-00372]\]. Given the possibility of between-study variance, we used a random-effect model rather than a fixed-effect model. Cochran's Q test and *I^2^* statistic were applied to determine the between-study heterogeneity. A value of *I^2^* of 0%--25% represents insignificant heterogeneity, 26%--50% low heterogeneity, 51%--75% moderate heterogeneity and 76--100% high heterogeneity \[[@B87-jcm-08-00372]\]. The presence of publication bias was assessed by the Egger test \[[@B88-jcm-08-00372]\].

3. Results {#sec3-jcm-08-00372}
==========

A total of 2525 potentially eligible articles were identified using our search strategy. After the exclusion of 1994 articles based on title and abstract for clearly not fulfilling inclusion criteria on the basis of type of article, patient population, study design, or outcome of interest, and 417 due to being duplicates, 114 articles were left for full-length review. Thirty-six of them were excluded from the full-length review as they did not report the outcome of interest, while 17 were excluded because they were not observational studies or clinical trials. Twenty-three studies were subsequently excluded because they did not use a standard AKI definition. Thus, we included 38 cohort studies \[[@B14-jcm-08-00372],[@B18-jcm-08-00372],[@B19-jcm-08-00372],[@B21-jcm-08-00372],[@B28-jcm-08-00372],[@B29-jcm-08-00372],[@B30-jcm-08-00372],[@B31-jcm-08-00372],[@B32-jcm-08-00372],[@B39-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B55-jcm-08-00372],[@B56-jcm-08-00372],[@B57-jcm-08-00372],[@B58-jcm-08-00372],[@B59-jcm-08-00372],[@B60-jcm-08-00372],[@B62-jcm-08-00372],[@B63-jcm-08-00372],[@B64-jcm-08-00372],[@B65-jcm-08-00372],[@B66-jcm-08-00372],[@B69-jcm-08-00372],[@B70-jcm-08-00372],[@B72-jcm-08-00372],[@B73-jcm-08-00372],[@B74-jcm-08-00372],[@B75-jcm-08-00372],[@B76-jcm-08-00372],[@B77-jcm-08-00372],[@B78-jcm-08-00372],[@B79-jcm-08-00372],[@B80-jcm-08-00372]\] in the meta-analysis of post-LTx AKI incidence with 13,422 patients enrolled. The literature retrieval, review, and selection process are demonstrated in [Figure 1](#jcm-08-00372-f001){ref-type="fig"}. The characteristics of the included studies are presented in [Table 1](#jcm-08-00372-t001){ref-type="table"}.

3.1. Incidence of Post-LTx AKI {#sec3dot1-jcm-08-00372}
------------------------------

Overall, the pooled estimated incidence rates of post-LTx AKI and severe AKI requiring RRT following LTx were 40.7% (95% CI: 35.4%--46.2%, *I*^2^ = 97%, [Figure 2](#jcm-08-00372-f002){ref-type="fig"}) and 7.7% (95% CI: 5.1%--11.4%, *I*^2^ = 95%, [Figure 3](#jcm-08-00372-f003){ref-type="fig"}), respectively.

Meta-regression showed no significant impact of type of donor (deceased vs living donors) (*p* = 0.33) on the incidence of post-LTx AKI. In addition, the year of study (*p* = 0.81) did not significantly affect the incidence of post-LTx AKI ([Figure 4](#jcm-08-00372-f004){ref-type="fig"}).

3.2. Risk Factors for Post-LTx AKI {#sec3dot2-jcm-08-00372}
----------------------------------

Reported risk factors for post-LTx AKI are demonstrated in [Table 2](#jcm-08-00372-t002){ref-type="table"}. Higher pretransplant SCr \[[@B11-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372]\], high body mass index (BMI) \[[@B39-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372],[@B67-jcm-08-00372]\], high MELD/MELD-Na score \[[@B23-jcm-08-00372],[@B39-jcm-08-00372],[@B40-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B45-jcm-08-00372],[@B46-jcm-08-00372],[@B47-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372]\], intraoperative blood loss and perioperative blood transfusion \[[@B18-jcm-08-00372],[@B25-jcm-08-00372],[@B39-jcm-08-00372],[@B48-jcm-08-00372],[@B54-jcm-08-00372],[@B65-jcm-08-00372]\], high APACHE II score \[[@B25-jcm-08-00372],[@B43-jcm-08-00372],[@B48-jcm-08-00372],[@B55-jcm-08-00372]\], hypotension and vasopressor requirement \[[@B18-jcm-08-00372],[@B24-jcm-08-00372],[@B48-jcm-08-00372],[@B54-jcm-08-00372]\], cold and warm ischemia time \[[@B14-jcm-08-00372],[@B35-jcm-08-00372],[@B78-jcm-08-00372]\], graft dysfunction \[[@B11-jcm-08-00372],[@B40-jcm-08-00372],[@B53-jcm-08-00372]\], post-reperfusion syndrome \[[@B20-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372],[@B75-jcm-08-00372],[@B78-jcm-08-00372]\], infection prior to transplant \[[@B25-jcm-08-00372],[@B45-jcm-08-00372],[@B48-jcm-08-00372]\], and hypoalbuminemia \[[@B18-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372]\] were consistently identified as important risk factors for Post-LTx AKI.

3.3. Impacts of Post-LTx AKI on Patient Outcomes {#sec3dot3-jcm-08-00372}
------------------------------------------------

The impacts of post-LTx AKI on patient outcomes are demonstrated in [Table 3](#jcm-08-00372-t003){ref-type="table"}. Overall, the pooled estimated in-hospital or 30-day mortality, and 1-year mortality rates of patients with post-LTx AKI were 16.5% (95% CI: 10.8%--24.3%, *I*^2^ = 94%) and 31.1% (95% CI: 22.4%--41.5%, *I*^2^ = 78%), respectively. Post-LTx AKI was associated with significantly higher mortality with a pooled OR of 2.96 (95% CI: 2.32--3.77, *I*^2^ = 59%). In addition, severe post-LTx AKI requiring RRT was associated with significantly higher mortality with a pooled OR of 8.15 (95% CI: 4.52--14.69, *I*^2^ = 90%). Compared to those without post-LTx AKI, recipients with post-LTx AKI had significantly increased risks of liver graft failure and CKD with pooled ORs of 3.76 (95% CI: 1.56--9.03, *I*^2^ = 91%, [Figure 5](#jcm-08-00372-f005){ref-type="fig"}) and 2.35 (95% CI: 1.53--3.61, *I*^2^ = 75%, [Figure 6](#jcm-08-00372-f006){ref-type="fig"}), respectively. AKI was associated with prolonged intensive care (ICU) and hospital stay \[[@B17-jcm-08-00372],[@B18-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B29-jcm-08-00372],[@B32-jcm-08-00372],[@B35-jcm-08-00372],[@B40-jcm-08-00372],[@B42-jcm-08-00372],[@B44-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B53-jcm-08-00372],[@B61-jcm-08-00372],[@B64-jcm-08-00372],[@B75-jcm-08-00372],[@B78-jcm-08-00372]\] ([Table 3](#jcm-08-00372-t003){ref-type="table"}).

3.4. Evaluation for Publication Bias {#sec3dot4-jcm-08-00372}
------------------------------------

Funnel plot ([Supplementary Figure S1](#app1-jcm-08-00372){ref-type="app"}) and Egger's regression asymmetry test were performed to evaluate for publication bias in the analysis evaluating incidence of post-LTx AKI and mortality risk of post-LTx AKI. There was no significant publication bias in meta-analysis assessing the incidence of post-LTx AKI, *p*-value = 0.12.

4. Discussion {#sec4-jcm-08-00372}
=============

In this meta-analysis, we found that AKI and severe AKI requiring RRT after LTx are common, with an incidence of 40.8% and 7.0%, respectively. In addition, our findings showed no significant correlation between the incidence of post-LTx AKI and study year for the ten years of the study. Furthermore, compared to patients without post-LTx AKI, those with post-LTx AKI carry a 2.96-fold increased risk of mortality and a 3.76-fold higher risk of liver graft failure.

The development of post-LTx AKI appears to be multifactorial with a number of preoperative, intraoperative and postoperative factors involved \[[@B90-jcm-08-00372]\]. Pre-LTx factors include high MELD/MELD-Na score, high APACHE II score, hypoalbuminemia, and reduced eGFR \[[@B11-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372]\]. Preexisting renal impairment is common among patients with end-stage liver disease \[[@B91-jcm-08-00372]\]. Although cirrhotic patients with significant CKD are eligible to receive a combined liver-kidney transplantation \[[@B92-jcm-08-00372]\], a lower baseline GFR among those who received LTx alone remained an important risk factor for post-operative AKI \[[@B11-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372]\]. Studies have demonstrated that hepatorenal syndrome before LTx can also lead to renal insufficiency and render LTx recipients more susceptible to post-LTx AKI \[[@B22-jcm-08-00372],[@B90-jcm-08-00372],[@B93-jcm-08-00372]\]. In addition, sepsis, graft dysfunction, thrombotic microangiopathy, and calcineurin inhibitor nephrotoxicity may all contribute to AKI \[[@B22-jcm-08-00372],[@B37-jcm-08-00372],[@B94-jcm-08-00372],[@B95-jcm-08-00372],[@B96-jcm-08-00372]\].

Studies have shown that higher MELD scores were associated with post-LTx AKI \[[@B23-jcm-08-00372],[@B39-jcm-08-00372],[@B40-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B45-jcm-08-00372],[@B46-jcm-08-00372],[@B47-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372]\]. In patients with high MELD scores \>30, the majority required RRT post LTx \[[@B44-jcm-08-00372],[@B97-jcm-08-00372]\]. Although SCr is an important determinant of the MELD score, other components of MELD such as pre-LTx INR has also been demonstrated to be strongly associated with post-LT AKI, suggesting that the severity of the liver disease itself, as reflected by the MELD score, is associated with post-LT AKI \[[@B45-jcm-08-00372]\]. Identified perioperative factors for post-LTx AKI include cardiopulmonary failure, vasopressor requirement, hemodynamic effects of prolonged surgery, and blood loss/RBC transfusion \[[@B18-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B39-jcm-08-00372],[@B48-jcm-08-00372],[@B54-jcm-08-00372],[@B65-jcm-08-00372]\]. Moreover, it has been hypothesized that HIRI is an important cause of post-LTx AKI \[[@B37-jcm-08-00372],[@B38-jcm-08-00372]\]. Aspartate aminotransferase (AST), as a surrogate marker for HIRI, has been shown to be correlated with post-LTx AKI. \[[@B38-jcm-08-00372],[@B78-jcm-08-00372]\] HIRI has a close relationship with the systemic inflammatory response, which in turn is related to AKI and multiorgan dysfunction in similar settings such as sepsis \[[@B37-jcm-08-00372]\]. Early hepatic graft dysfunction has also been shown to be associated to post-LTx AKI \[[@B98-jcm-08-00372]\]. In addition, recipients of donation after circulatory death (DCD) grafts are reported to have a higher incidence of post-LTx AKI compared to donation after brain death (DBD grafts). After DCD LTx, peak AST levels were an independent predictor of post-LTx AKI \[[@B99-jcm-08-00372]\]. Other known factors that influence HIRI such as donor age, cold and warm ischemia times and graft steatosis have also been associated with post-LTx AKI \[[@B37-jcm-08-00372]\].

As demonstrated in our study, post-LTx AKI is associated with an increased risk of death and liver graft failure. Several pharmacological and non-pharmacological interventions have been studied, but so far these have failed to demonstrate any significant benefit in the prevention of post-LTx AKI \[[@B37-jcm-08-00372],[@B100-jcm-08-00372],[@B101-jcm-08-00372]\]. To continue efforts to mitigate post-LTx AKI, it is important to identify those who are at high-risk for post-LTx AKI in order to develop earlier protective strategies \[[@B37-jcm-08-00372]\]. There have been many attempts to develop predictive models for post-LTx AKI \[[@B37-jcm-08-00372]\]. Seven published predictive models addressing a diverse range of AKI definitions for post-LT AKI have been developed \[[@B19-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B33-jcm-08-00372],[@B47-jcm-08-00372],[@B54-jcm-08-00372],[@B55-jcm-08-00372]\]. However, the numbers of patients in these studies were limited \[[@B19-jcm-08-00372],[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B33-jcm-08-00372],[@B47-jcm-08-00372],[@B54-jcm-08-00372],[@B55-jcm-08-00372]\], and future prospective external validation, ideally with multi-center studies with large number of patients, is required.

Several limitations in our meta-analysis are worth mentioning. First, there were statistical heterogeneities present in our study. Possible sources for heterogeneities were the differences in the patient characteristics in the individual studies. However, we performed a meta-regression analysis which demonstrated that the type of donor (deceased vs. living donors); the year of study did not significantly affect the incidence of post-LTx AKI. Second, there is a lack of data from included studies on novel AKI biomarkers. Novel biomarkers for AKI are emerging and could be useful for the early identification and characterization of AKI. Thus, future studies evaluating predictive models with novel biomarkers are needed. Lastly, this is a systematic review and meta-analysis of cohort studies. Thus, it can demonstrate associations of post-LTx AKI with increased risk of mortality and liver graft failure, but not a causal relationship.

5. Conclusions {#sec5-jcm-08-00372}
==============

In conclusion, there are overall high incidence rates of post-LTx AKI and severe AKI requiring RRT of 40.8% and 7.0%. Post-LTx AKI is significantly associated with increased mortality and liver graft failure. In addition, the incidence of post-LTx AKI has remained stable over time. This study provides an epidemiological perspective to support the need for future large-scale multi-center studies to identify preventive strategies for post-LTx AKI.

None. All authors had access to the data and played essential roles in writing of the manuscript.

The following are available online at <https://www.mdpi.com/2077-0383/8/3/372/s1>, Figure S1: Funnel plot evaluating for publication bias evaluating incidence of post-LTx AKI.

###### 

Click here for additional data file.

Conceptualization, M.A.M. and W.C.; Data curation, C.T., N.T., and K.W. Formal analysis, C.T. and W.C.; Investigation, C.T., N.T., T.B., P.L., K.S., S.A.S., P.U. and W.C.; Methodology, C.T., W.K., T.B., P.U., K.W., P.T.K., N.R.A. and W.C.; Project administration, W.K., T.B., K.W., P.L., K.S. and S.A.S.; Resources, T.B., K.W., P.L., K.S. and S.A.S. and P.U.; Software, K.W.; Supervision, W.K., M.A.M. and W.C.; Validation, P.U., M.A.M. and W.C.; Visualization, W.C.; Writing---original draft, C.T.; Writing---review & editing, C.T., W.K., N.T., T.B., K.W., P.L., K.S. and S.A.S., P.U., K.W., P.T.K., N.R.A., M.A.M. and W.C.

The authors declare no conflict of interest.

![Outline of our search methodology.](jcm-08-00372-g001){#jcm-08-00372-f001}

![Forest plots of the included studies assessing incidence rates of post-LTx AKI. A diamond data marker represents the overall rate from each included study (square data marker) and 95% confidence interval.](jcm-08-00372-g002){#jcm-08-00372-f002}

![Forest plots of the included studies assessing incidence rates of severe AKI requiring RRT following LTx. A diamond data marker represents the overall rate from each included study (square data marker) and 95% confidence interval.](jcm-08-00372-g003){#jcm-08-00372-f003}

![Meta-regression analyses showed no significant impact of year of study on the incidence of post-LTx AKI (*p* = 0.81). The solid black line represents the weighted regression line based on variance-weighted least squares. The inner and outer lines show the 95% confidence interval and prediction interval around the regression line. The circles indicate log event rates in each study.](jcm-08-00372-g004){#jcm-08-00372-f004}

![Forest plots of the included studies assessing liver graft failure among patients with post-LTx AKI. A diamond data marker represents the overall rate from each included study (square data marker) and 95% confidence interval.](jcm-08-00372-g005){#jcm-08-00372-f005}

![Forest plots of the included studies assessing CKD risk among patients with post-LTx AKI. A diamond data marker represents the overall rate from each included study (square data marker) and 95% confidence interval.](jcm-08-00372-g006){#jcm-08-00372-f006}
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###### 

Main characteristics of studies included in meta-analysis of AKI in patients undergoing LTx \[[@B14-jcm-08-00372],[@B18-jcm-08-00372],[@B19-jcm-08-00372],[@B21-jcm-08-00372],[@B28-jcm-08-00372],[@B29-jcm-08-00372],[@B30-jcm-08-00372],[@B31-jcm-08-00372],[@B32-jcm-08-00372],[@B39-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B55-jcm-08-00372],[@B56-jcm-08-00372],[@B57-jcm-08-00372],[@B58-jcm-08-00372],[@B59-jcm-08-00372],[@B60-jcm-08-00372],[@B62-jcm-08-00372],[@B63-jcm-08-00372],[@B64-jcm-08-00372],[@B65-jcm-08-00372],[@B66-jcm-08-00372],[@B69-jcm-08-00372],[@B70-jcm-08-00372],[@B72-jcm-08-00372],[@B73-jcm-08-00372],[@B74-jcm-08-00372],[@B75-jcm-08-00372],[@B76-jcm-08-00372],[@B77-jcm-08-00372],[@B78-jcm-08-00372],[@B79-jcm-08-00372],[@B80-jcm-08-00372]\].

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                               Year   Country        Procedure/Patients                                             Number   Deceased Donor   AKI Definition                                                                                           Incidence                         Mortality in AKI
  --------------------------------------------------- ------ -------------- -------------------------------------------------------------- -------- ---------------- -------------------------------------------------------------------------------------------------------- --------------------------------- ---------------------
  O'riordan et al. \[[@B32-jcm-08-00372]\]            2007   Ireland        Deceased donor orthotopic liver transplant                     350      350 (100%)       ARI/ARF; RIFLE Injury and Failure stage within 2 weeks after transplant                                  ARI/ARF\                          1-year mortality\
                                                                                                                                                                                                                                                                              129/350 (36.9%)\                  56/129 (43%)
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              68/350 (19.4%)                    

  Kundakci et al. \[[@B41-jcm-08-00372]\]             2010   Turkey         Orthotopic liver transplant                                    112      75 (67%)         AKI; RIFLE criteria                                                                                      AKI\                              1-year mortality\
                                                                                                                                                                                                                                                                              64/112 (57.1%)                    23/64 (36%)

  Portal et al. \[[@B55-jcm-08-00372]\]               2010   UK             Liver transplant                                               80       N/A              AKI; AKIN criteria within 48 hours after transplants                                                     AKI\                              N/A
                                                                                                                                                                                                                                                                              30/80 (37.5%)                     

  Zhu et al. \[[@B42-jcm-08-00372]\]                  2010   China          Deceased donor orthotopic liver transplant                     193      193 (100%)       AKI; AKIN criteria within 28 days after transplants                                                      AKI\                              1-year mortality\
                                                                                                                                                                                                                                                                              116/193 (60.1%)\                  30/116 (26%)
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              10/193 (5.2%)                     

  Lee et al. \[[@B56-jcm-08-00372]\]                  2010   Korea          Liver transplant                                               431      99 (23%)         AKI; RIFLE criteria                                                                                      AKI\                              N/A
                                                                                                                                                                                                                                                                              118/431 (27.4%)\                  
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              14/431 (3.2%)                     

  Ferreira et al. \[[@B57-jcm-08-00372]\]             2010   Portugal       Orthotopic liver transplant                                    708      N/A              AKI; RIFLE criteria within 21 days after transplant                                                      AKI\                              Mortality\
                                                                                                                                                                                                                                                                              235/708 (33.2%)\                  43/235 (18%)
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              73/708 (10.3%)                    

  Tinti et al. \[[@B58-jcm-08-00372]\]                2010   Italy          Deceased donor orthotopic liver transplant                     24       24 (100%)        AKI; RIFLE criteria within 15 days after transplant                                                      AKI\                              N/A
                                                                                                                                                                                                                                                                              9/24 (37.5%)                      

  Chen et al. (1) \[[@B18-jcm-08-00372]\]             2011   USA            Liver transplant                                               334      N/A              ARI/ARF; RIFLE Injury and Failure stage within 2 weeks after transplant within 7 days after transplant   ARI/ARF\                          Mortality\
                                                                                                                                                                                                                                                                              118/334 (38.3%)                   13/118 (11%)

  Umbro et al. \[[@B59-jcm-08-00372]\]                2011   Italy          Deceased donor liver transplant                                46       46 (100%)        AKI; RIFLE criteria within 7 days after transplant                                                       AKI\                              N/A
                                                                                                                                                                                                                                                                              26/46 (56.5%)                     

  Karapanagiotou et al. (1) \[[@B43-jcm-08-00372]\]   2012   Greece         Orthotopic liver transplant                                    75       N/A              AKI; an increase in SCr 1.5 times above baseline or value \> 2.0 mg/dL within 7 days after transplant    AKI\                              1-year mortality\
                                                                                                                                                                                                                                                                              22/75 (29.3%)\                    11/22 (50%)
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              7/75 (9.3%)                       

  Utsumi et al. \[[@B44-jcm-08-00372]\]               2013   Japan          Living donor liver transplant                                  200      0 (0%)           AKI; RIFLE criteria within 28 days after transplants                                                     AKI\                              Hospital mortality\
                                                                                                                                                                                                                                                                              121/200 (60.5%)\                  AKI\
                                                                                                                                                                                                                                                                              ARI/ARF\                          14/121 (12%)\
                                                                                                                                                                                                                                                                              74/200 (37%)                      ARI/ARF\
                                                                                                                                                                                                                                                                                                                12/74(16%)\
                                                                                                                                                                                                                                                                                                                1-year mortality\
                                                                                                                                                                                                                                                                                                                AKI\
                                                                                                                                                                                                                                                                                                                24/121 (20%)\
                                                                                                                                                                                                                                                                                                                ARI/ARF\
                                                                                                                                                                                                                                                                                                                22/74 (30%)

  Narciso et al. \[[@B60-jcm-08-00372]\]              2013   Brazil         Liver transplant                                               315      181 (57%)        AKI; AKIN criteria within 48 hours after transplants                                                     AKI\                              Dialysis\
                                                                                                                                                                                                                                                                              48 hours: 101/315 (32.1%)\        28/48 (58%)
                                                                                                                                                                                                                                                                              1 week: 255/315 (81%)\            
                                                                                                                                                                                                                                                                              Hospitalization: 293/315 (93%)\   
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              Any: 48/315 (15.2%)\              
                                                                                                                                                                                                                                                                              1 week: 31/315 (9.8%)             

  Leithead et al. \[[@B39-jcm-08-00372]\]             2014   UK             Liver transplant                                               1152     1152 (100%)\     AKI; KDIGO criteria within 7 days after transplants                                                      AKI\                              AKI\
                                                                                                                                                    DCD 112 (10%)                                                                                                             381/1152 (33.1%)\                 152/381 (40%)
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              238/1152 (20.7%)                  

  Karapanagiotou et al. (2) \[[@B48-jcm-08-00372]\]   2014   Greece         Liver transplant                                               71       N/A              AKI; RIFLE within 7 days or AKIN criteria within 48 hours                                                RIFLE AKI\                        6-month mortality\
                                                                                                                                                                                                                                                                              28/71 (39.4%)\                    RIFLE AKI\
                                                                                                                                                                                                                                                                              AKIN AKI\                         15/28 (54%)\
                                                                                                                                                                                                                                                                              37/71 (52.1%)                     AKIN AKI\
                                                                                                                                                                                                                                                                                                                17/37 (46%)

  Nadeem et al. \[[@B49-jcm-08-00372]\]               2014   Saudi Arabia   Liver transplant                                               158      N/A              AKI; RIFLE criteria within 72 hours after transplants                                                    AKI\                              N/A
                                                                                                                                                                                                                                                                              57/158 (36.1%)                    

  Lewandowska et al. \[[@B62-jcm-08-00372]\]          2014   Poland         Orthotopic liver transplant                                    63       N/A              AKI; RIFLE criteria within 72 hours after transplant                                                     AKI\                              N/A
                                                                                                                                                                                                                                                                              35/63 (55.6%)                     

  Barreto et al. \[[@B63-jcm-08-00372]\]              2015   Brazil         Orthotopic liver transplant                                    134      N/A              AKI; AKIN criteria 2 or 3 within 72 hours after transplants                                              AKIN stage 2 or 3\                N/A
                                                                                                                                                                                                                                                                              64/134 (47.8%)\                   
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              33/134 (24.6%)                    

  Hilmi et al. \[[@B19-jcm-08-00372]\]                2015   USA            Deceased donor liver transplant                                424      424 (100%)\      AKI; KDIGO criteria within 72 hours after transplant                                                     AKI\                              30-day mortality\
                                                                                                                                                    EDC 257 (61%)                                                                                                             221/424 (52.1%)                   3/221 (1%)

  Park et al. \[[@B64-jcm-08-00372]\]                 2015   Korea          Living donor liver transplant                                  538      0 (0%)           AKI; RIFLE criteria within 30 days after transplant                                                      AKI\                              Hospital mortality\
                                                                                                                                                                                                                                                                              147/538 (27.3%)\                  26/147 (18%)\
                                                                                                                                                                                                                                                                              Dialysis\                         1-year mortality\
                                                                                                                                                                                                                                                                              34/538 (6.3%)                     29/147 (20%)

  Mukhtar et al. \[[@B65-jcm-08-00372]\]              2015   Egypt          Living donor liver transplant                                  303      0 (0%)           AKI; AKIN criteria within 96 hours after transplant                                                      AKI\                              N/A
                                                                                                                                                                                                                                                                              115/303 (38%)\                    
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              28/303 (9.2%)                     

  Sang et al. \[[@B66-jcm-08-00372]\]                 2015   Korea          Living donor liver transplant                                  998      0 (0%)           AKI; RIFLE or AKIN criteria within 7 days after transplant                                               RIFLE AKI\                        RIFLE AKI\
                                                                                                                                                                                                                                                                              709/998 (71.0%)\                  79/709 (11%)\
                                                                                                                                                                                                                                                                              AKIN AKI\                         AKIN AKI\
                                                                                                                                                                                                                                                                              593/998 (59.4%)                   66/593 (11%)

  Biancofiore et al. \[[@B69-jcm-08-00372]\]          2015   Italy          Deceased donor liver transplant                                295      295 (100%)       AKI; AKIN criteria within 7 days after transplant                                                        AKIN stage 2 AKI\                 N/A
                                                                                                                                                                                                                                                                              51/295 (17.3%)                    

  Jun et al. \[[@B70-jcm-08-00372]\]                  2016   Korea          Living donor liver transplant                                  1617     0 (0%)           AKI; KDIGO criteria within 7 days after transplant                                                       AKI\                              N/A
                                                                                                                                                                                                                                                                              999/1617 (61.8%)\                 
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              9/448 (2%)                        

  Erdost et al. \[[@B72-jcm-08-00372]\]               2016   Turkey         Liver transplant                                               440      194 (44%)        AKI; RIFLE, AKIN, KDIGO criteria within 7 days after transplant                                          RIFLE AKI\                        30-day mortality\
                                                                                                                                                                                                                                                                              35/440 (8.0%)\                    RIFLE AKI\
                                                                                                                                                                                                                                                                              AKIN AKI\                         8/35 (23%)\
                                                                                                                                                                                                                                                                              63/440 (14.3%)\                   AKIN AKI\
                                                                                                                                                                                                                                                                              KDIGO AKI\                        34/63 (54%)\
                                                                                                                                                                                                                                                                              64/440 (14.5%)                    KDIGO AKI\
                                                                                                                                                                                                                                                                                                                35/64 (55%)

  Kamei et al. \[[@B73-jcm-08-00372]\]                2016   Japan          Liver transplant                                               62       DBD 4 (6%)       AKI; RIFLE injury or failure stage within 4 weeks after transplant                                       AKI\                              N/A
                                                                                                                                                                                                                                                                              13/62 (21%)\                      
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              4/62 (6.5%)                       

  Mizota et al. (1) \[[@B74-jcm-08-00372]\]           2016   Japan          Living donor liver transplant                                  320      0 (0%)           AKI; KDIGO criteria within 7 days after transplant                                                       AKI\                              Hospital mortality\
                                                                                                                                                                                                                                                                              199/320 (62.2%)                   39/199 (20%)

  Sun et al. \[[@B21-jcm-08-00372]\]                  2017   USA            Liver transplant                                               1037     N/A              AKI; AKIN criteria within 48 hours after transplant                                                      AKI\                              N/A
                                                                                                                                                                                                                                                                              549/1037 (54.9%)                  

  Chae et al. \[[@B75-jcm-08-00372]\]                 2017   Korea          Living donor liver transplant                                  334      0 (0%)           AKI; AKIN criteria within 48 hours after transplant                                                      AKI\                              Hospital mortality\
                                                                                                                                                                                                                                                                              76/334 (22.7%)                    10/76 (13.2%)

  Mizota et al. (2) \[[@B76-jcm-08-00372]\]           2017   Japan          Living donor liver transplant                                  231      0 (0%)           Severe AKI; KDIGO stage 2 or 3 criteria within 7 days after transplant                                   Severe AKI\                       Hospital mortality\
                                                                                                                                                                                                                                                                              71/231 (30.7%)                    23/71 (32.4%)

  Trinh et al. \[[@B77-jcm-08-00372]\]                2017   Canada         Deceased donor liver transplant                                491      491 (100%)       AKI; KDIGO criteria within 7 days after transplant                                                       AKI\                              N/A
                                                                                                                                                                                                                                                                              278/491 (56.6%)                   

  Kalisvaart et al. \[[@B78-jcm-08-00372]\]           2017   Netherlands    Donation after brain death liver transplant                    155      155 (100%)\      AKI; AKIN criteria within 7 days after transplant                                                        AKI\                              Hospital mortality\
                                                                                                                                                    DBD 155 (100%)                                                                                                            61/155 (39.4%)\                   9/61 (15%)
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              5/155 (3.2%)                      

  Chen et al. (2) \[[@B79-jcm-08-00372]\]             2017   China          Liver transplant in hepatocellular carcinoma                   566      N/A              AKI; AKIN criteria within 48 hours after transplant                                                      AKI\                              30-day mortality\
                                                                                                                                                                                                                                                                              109/566 (19.3%)\                  9/109 (8%)
                                                                                                                                                                                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              13/566 (2.3%)                     

  Baron-Stefaniak et al. \[[@B80-jcm-08-00372]\]      2017   Austria        Orthotopic liver transplant                                    45       N/A              AKI; KDIGO criteria within 48 hours after transplant                                                     AKI\                              N/A
                                                                                                                                                                                                                                                                              34/45 (75.6)                      

  Zhou et al. \[[@B30-jcm-08-00372]\]                 2017   China          Donation after circulatory death orthotopic liver transplant   103      103 (100%)\      AKI; KDIGO criteria within 7 days after transplant                                                       AKI\                              N/A
                                                                                                                                                    DCD 103 (100%)                                                                                                            42/103 (40.8%)\                   
                                                                                                                                                                                                                                                                              CRRT\                             
                                                                                                                                                                                                                                                                              7/103 (6.8%)                      

  Yoo et al. \[[@B31-jcm-08-00372]\]                  2017   Korea          Liver transplant                                               304      84 (28%)         AKI; RIFLE criteria within 7 days after transplant                                                       AKI\                              N/A
                                                                                                                                                                                                                                                                              132/304 (43.4%)                   

  Jochmans \[[@B29-jcm-08-00372]\]                    2017   Belgium        Orthotopic liver transplant                                    80       80 (100%)\       AKI; RIFLE criteria within 5 days after reperfusion                                                      AKI\                              1-year mortality\
                                                                                                                                                    DCD 13 (16%)\                                                                                                             21/80 (26.3%)\                    2/21 (10%)
                                                                                                                                                    DBD 67 (84%)                                                                                                              Dialysis\                         
                                                                                                                                                                                                                                                                              4/80 (5%)                         

  Kandil et al. \[[@B28-jcm-08-00372]\]               2017   Egypt          Living donor liver transplant                                  50       0 (0%)           AKI; AKIN criteria within 48 hours                                                                       AKI\                              N/A
                                                                                                                                                                                                                                                                              23/50 (46%)                       

  Kim et al. \[[@B14-jcm-08-00372]\]                  2018   Korea          Living donor liver transplant                                  583      0 (0%)           AKI; KDIGO criteria within 7 days after transplant                                                       AKI\                              N/A
                                                                                                                                                                                                                                                                              205/583 (35.2%)                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKIN, Acute Kidney Injury Network; DCD, donation after circulatory death; EDC, extended donor criteria liver allografts; KDIGO, Kidney Disease Improving Global Outcomes; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; UK, United Kingdom; USA, United States of America.
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###### 

Reported Potential Predictors/Associated-Risk Factors of Post-LTx AKI.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Donor and Graft Factors                                                                                                                       Recipient Factors                                                                                                                                                                                                                                                                                                                            Surgical and Postoperative Factors
  --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cold ischemia time \[[@B14-jcm-08-00372],[@B35-jcm-08-00372],[@B78-jcm-08-00372]\],\                                                          Higher MELD score/MELD-Na \[[@B23-jcm-08-00372],[@B39-jcm-08-00372],[@B40-jcm-08-00372],[@B41-jcm-08-00372],[@B42-jcm-08-00372],[@B43-jcm-08-00372],[@B44-jcm-08-00372],[@B45-jcm-08-00372],[@B46-jcm-08-00372],[@B47-jcm-08-00372],[@B48-jcm-08-00372],[@B49-jcm-08-00372],[@B64-jcm-08-00372],[@B67-jcm-08-00372],[@B89-jcm-08-00372]\]\   Intra-operative hypotension, low MAP \[[@B24-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B54-jcm-08-00372],[@B66-jcm-08-00372],[@B79-jcm-08-00372]\]\
  warm ischemic time \[[@B35-jcm-08-00372],[@B39-jcm-08-00372],[@B63-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372]\]\                   APACHE II25 \[[@B43-jcm-08-00372],[@B48-jcm-08-00372],[@B55-jcm-08-00372]\],\                                                                                                                                                                                                                                                                Inotrope/vasopressor requirement \[[@B18-jcm-08-00372],[@B30-jcm-08-00372],[@B32-jcm-08-00372],[@B48-jcm-08-00372],[@B65-jcm-08-00372]\], dopamine \[[@B35-jcm-08-00372]\], intra-operative need of noradrenaline \[[@B33-jcm-08-00372],[@B67-jcm-08-00372]\]\
  Small-for-size graft/Graft-recipient body weight ratio \[[@B40-jcm-08-00372],[@B44-jcm-08-00372],[@B65-jcm-08-00372],[@B66-jcm-08-00372]\]\   Preoperative SCr11 \[[@B23-jcm-08-00372],[@B24-jcm-08-00372],[@B25-jcm-08-00372],[@B32-jcm-08-00372],[@B33-jcm-08-00372],[@B34-jcm-08-00372],[@B35-jcm-08-00372]\]\                                                                                                                                                                          Duration of treatment with dopamine \[[@B53-jcm-08-00372]\]\
  Deceased donor \[[@B20-jcm-08-00372],[@B47-jcm-08-00372]\]\                                                                                   Preoperative BUN \[[@B23-jcm-08-00372],[@B24-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                Blood loss \[[@B35-jcm-08-00372],[@B44-jcm-08-00372],[@B47-jcm-08-00372],[@B64-jcm-08-00372],[@B70-jcm-08-00372],[@B71-jcm-08-00372]\], RBC transfusion \[[@B14-jcm-08-00372],[@B18-jcm-08-00372],[@B25-jcm-08-00372],[@B33-jcm-08-00372],[@B39-jcm-08-00372],[@B48-jcm-08-00372],[@B54-jcm-08-00372],[@B65-jcm-08-00372],[@B66-jcm-08-00372],[@B72-jcm-08-00372],[@B89-jcm-08-00372]\]\
  Graft dysfunction \[[@B11-jcm-08-00372],[@B53-jcm-08-00372]\]\                                                                                Preoperative renal dysfunction/ARF \[[@B40-jcm-08-00372],[@B43-jcm-08-00372],[@B53-jcm-08-00372]\]\                                                                                                                                                                                                                                          Need of cryoprecipitate \[[@B64-jcm-08-00372]\]\
  DCD \[[@B39-jcm-08-00372]\]\                                                                                                                  Child-Pugh score \[[@B19-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                                    Anesthetic/Operation time \[[@B30-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372],[@B70-jcm-08-00372]\]\
  ABO incompatibility \[[@B70-jcm-08-00372]\]\                                                                                                  SOFA \[[@B48-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                                                Post-reperfusion syndrome \[[@B20-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372],[@B78-jcm-08-00372]\]\
  Lower donor BMI \[[@B39-jcm-08-00372]\]\                                                                                                      Male sex \[[@B42-jcm-08-00372]\], female sex \[[@B19-jcm-08-00372],[@B31-jcm-08-00372]\]\                                                                                                                                                                                                                                                    SvO2 reduction with oliguria \[[@B14-jcm-08-00372]\], Oxygen content 5 min after graft reperfusion \[[@B75-jcm-08-00372]\]\
  Older donor age \[[@B39-jcm-08-00372]\]                                                                                                       Preoperative hepatic encephalopathy \[[@B47-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                 Terlipressin (protective) \[[@B65-jcm-08-00372]\]\
                                                                                                                                                Infection \[[@B25-jcm-08-00372],[@B48-jcm-08-00372],[@B71-jcm-08-00372]\]\                                                                                                                                                                                                                                                                   Venovenous bypass (protective) \[[@B21-jcm-08-00372]\]\
                                                                                                                                                Hypoalbuminemia \[[@B18-jcm-08-00372],[@B53-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372]\]\                                                                                                                                                                                                                                         Postoperative ICU days \[[@B23-jcm-08-00372],[@B48-jcm-08-00372]\]\
                                                                                                                                                Preoperative low hemoglobin \[[@B14-jcm-08-00372],[@B72-jcm-08-00372]\]\                                                                                                                                                                                                                                                                     Duration of ventilator support \[[@B48-jcm-08-00372]\]\
                                                                                                                                                High body weight, BMI \[[@B14-jcm-08-00372],[@B19-jcm-08-00372],[@B39-jcm-08-00372],[@B44-jcm-08-00372],[@B64-jcm-08-00372],[@B66-jcm-08-00372],[@B67-jcm-08-00372],[@B75-jcm-08-00372]\]\                                                                                                                                                   Aminoglycoside use \[[@B32-jcm-08-00372]\]\
                                                                                                                                                Pretransplant hypertension \[[@B32-jcm-08-00372],[@B54-jcm-08-00372]\]\                                                                                                                                                                                                                                                                      Duration of anhepatic phase \[[@B41-jcm-08-00372],[@B79-jcm-08-00372]\]\
                                                                                                                                                Preoperative DM \[[@B19-jcm-08-00372],[@B44-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                 Intra-operative acidosis \[[@B41-jcm-08-00372]\]\
                                                                                                                                                Alcoholic liver disease \[[@B32-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                             Intra-operative urine output \[[@B14-jcm-08-00372],[@B24-jcm-08-00372],[@B30-jcm-08-00372],[@B33-jcm-08-00372]\]\
                                                                                                                                                Pretransplant hepatitis B and/or C \[[@B54-jcm-08-00372],[@B63-jcm-08-00372]\]\                                                                                                                                                                                                                                                              Overexposure to calcineurin inhibitor \[[@B35-jcm-08-00372],[@B44-jcm-08-00372],[@B64-jcm-08-00372]\]\
                                                                                                                                                Tumor as indication for transplant \[[@B47-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                  Need of diuretics \[[@B46-jcm-08-00372],[@B75-jcm-08-00372]\]\
                                                                                                                                                Elevated lactate \[[@B54-jcm-08-00372],[@B63-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                Chloride-liberal fluid received within the 24 h posttransplant \[[@B49-jcm-08-00372]\]\
                                                                                                                                                Elevated plasma NGAL \[[@B55-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                                Crystalloid administration \[[@B14-jcm-08-00372]\]\
                                                                                                                                                Hyponatremia \[[@B39-jcm-08-00372]\]\                                                                                                                                                                                                                                                                                                        Use of 6% HES \[[@B89-jcm-08-00372]\]\
                                                                                                                                                Pulmonary hypertension \[[@B31-jcm-08-00372]\]                                                                                                                                                                                                                                                                                               Mean blood glucose during the day of surgery \[[@B64-jcm-08-00372]\], glucose variability \[[@B31-jcm-08-00372]\]\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Peak AST occurring at 6 h \[[@B29-jcm-08-00372]\]

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations:: ABO incompatibility, incompatibility of the ABO blood group; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ALP, alkaline phosphatase; APACHE, Acute Physiology and Chronic Health Evaluation; ARI, acute renal injury; ARF, acute renal failure; AST, aspartate aminotransferase; ATG, Anti-thymocyte globulin; BMI, body mass index; BUN, blood urea nitrogen; CMV, cytomegalovirus; DBD, graft donated after brain death; DCD, donation after circulatory death; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FFP, fresh frozen plasma; HCV, hepatitis C virus; HES, hydroxyethyl starch; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; SCr, serum creatinine; MAP, mean arterial pressure; MELD, Model For End-Stage Liver Disease; MMF, mycophenolate mofetil; N/A, not available; NGAL, neutrophil gelatinase-associated lipocalin; PBC, primary biliary cirrhosis; RBC, red blood cell; RRT, renal replacement therapy; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; SOFA, Sequential Organ Failure Assessment; SvO2, mixed venous oxygen saturation.
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###### 

Reported Outcomes of Post-LTx AKI.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                            Outcomes                                                                                                    Confounder Adjustment
  ------------------------------------------------ ----------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bilbao et al. \[[@B11-jcm-08-00372]\]            Mortality\                                                                                                  None
                                                   Dialysis: 6.47 (2.73--15.35)\                                                                               
                                                   Graft failure\                                                                                              
                                                   Dialysis: 4.11 (1.81--9.32)                                                                                 

  Contreras et al. \[[@B24-jcm-08-00372]\]         Hospital mortality\                                                                                         None
                                                   Dialysis: 9.91 (3.45--28.51)\                                                                               
                                                   ICU LOS\                                                                                                    
                                                   Dialysis: 15 ± 13 vs. 7 ± 11 days\                                                                          
                                                   Hospital LOS\                                                                                               
                                                   Dialysis: 34 ± 27 vs. 19 ± 20 days                                                                          

  Lebrón Gallardo et al. \[[@B25-jcm-08-00372]\]   Mortality\                                                                                                  None
                                                   Early renal dysfunction: 2.47 (1.29--4.72)\                                                                 
                                                   Dialysis: 8.80 (3.65--21.23)                                                                                

  Sanchez et al. \[[@B23-jcm-08-00372]\]           1-year mortality\                                                                                           None
                                                   Dialysis: 9.07 (5.49--14.97)\                                                                               
                                                   ICU LOS\                                                                                                    
                                                   2.1 ± 3.0 in no dialysis vs. 8.6 ± 11.6 in hemodialysis vs. 10.5 ± 12.8 days in CRRT                        

  Wyatt et al. \[[@B22-jcm-08-00372]\]             Mortality\                                                                                                  Age, sex, race, DM, transplant centers
                                                   ARF without RRT: 8.69 (3.25--23.19)\                                                                        
                                                   ARF with RRT: 12.07 (3.90--37.32)                                                                           

  Cabezuelo et al. \[[@B53-jcm-08-00372]\]         ICU LOS\                                                                                                    N/A
                                                   ARF: 12.9 ± 7.4 vs. 7.2 ± 4.0 days                                                                          

  O'Riordan et al. \[[@B32-jcm-08-00372]\]         1-year mortality\                                                                                           DM, pretransplant, SCr, PBC, inotrope use, CMV infection/disease, rejection
                                                   ARF: 2.6 (1.5--4.5)\                                                                                        
                                                   Hospital LOS\                                                                                               
                                                   39.3 ± 79.5 in no ARI/ARF vs. 53.3 ± 72.8 in ARI vs. 73.0 ± 129.8 days in ARF                               

  Lee et al. \[[@B40-jcm-08-00372]\]               Hospital LOS\                                                                                               N/A
                                                   Renal dysfunction: 75 ± 144 vs. 45.2 ± 34.5 days                                                            

  Rueggeberg et al. \[[@B54-jcm-08-00372]\]        1-year mortality\                                                                                           None
                                                   AKI: 10.93 (3.64--32.83)                                                                                    

  Barri et al. \[[@B17-jcm-08-00372]\]             2-year mortality\                                                                                           None
                                                   AKI: 2.33 (1.53--3.53)\                                                                                     
                                                   2-year graft failure\                                                                                       
                                                   AKI: 2.56 (1.73--3.78)\                                                                                     
                                                   ICU LOS\                                                                                                    
                                                   AKI: 8 ± 19 vs. 3 ± 5 days\                                                                                 
                                                   Hospital LOS\                                                                                               
                                                   AKI: 20 ± 24 vs. 11 ± 10 days                                                                               

  Kundakci et al. \[[@B41-jcm-08-00372]\]          1-year mortality\                                                                                           None
                                                   AKI: 6.73 (2.15--21.06)                                                                                     

  Zhu et al. \[[@B42-jcm-08-00372]\]               1-year mortality\                                                                                           Hypertension, infection and APACHE II
                                                   AKI: 12.1 (1.57--93.54)\                                                                                    
                                                   ICU LOS\                                                                                                    
                                                   AKI: 6 (4--9) vs. 4 (3--5) days\                                                                            
                                                   Hospital LOS\                                                                                               
                                                   AKI: 29 (16--47) vs. 29 (20--48) days                                                                       

  Ferreira et al. \[[@B57-jcm-08-00372]\]          Mortality\                                                                                                  None
                                                   AKI: 0.73 (0.59--1.08)\                                                                                     
                                                   CKD\                                                                                                        
                                                   AKI: 4.84 (3.45--6.80)                                                                                      

  Lee et al. \[[@B56-jcm-08-00372]\]               CKD\                                                                                                        Age, sex, period of transplant, BMI, pretransplant DM, pretransplant hypertension, history of cardiovascular disease, donor type, underlying liver disease, HBV-related liver disease, hepatocellular carcinoma, use of adefovir, calcineurin inhibitors, purine metabolism inhibitors, acute rejection, pretransplant hemoglobin, pretransplant GFR, pretransplant proteinuria, hepatorenal syndrome, Child-Pugh score, MELD score
                                                   AKI: 1.54 (1.02--2.34)                                                                                      

  Chen et al. \[[@B18-jcm-08-00372]\]              1-year mortality\                                                                                           None
                                                   ARI/ARF: 2.79 (0.96--8.12)\                                                                                 
                                                   1-year graft failure\                                                                                       
                                                   ARI/ARF: 1.91 (0.89--4.09)\                                                                                 
                                                   Hospital LOS\                                                                                               
                                                   21.8 ± 22.1 in no ARI/ARF vs. 24 ± 25 in ARI and 37 ± 49 days in ARF                                        

  Karapanagiotou et al. \[[@B43-jcm-08-00372]\]    1-year mortality\                                                                                           Infection, hemorrhage, MELD, APACHE score
                                                   9.61 (1.48--62.55)                                                                                          

  Utsumi et al. \[[@B44-jcm-08-00372]\]            Hospital mortality\                                                                                         None
                                                   AKI: 5.04 (1.11--22.81)\                                                                                    
                                                   ARI/ARF: 5.90 (1.83--19.06)\                                                                                
                                                   1-year mortality\                                                                                           
                                                   AKI: 9.53 (2.18--41.56)\                                                                                    
                                                   ARI/ARF: 12.90 (4.24--39.30)\                                                                               
                                                   CKD\                                                                                                        
                                                   AKI: 15/107 (14%) vs. 0/77 (0%)\                                                                            
                                                   ARI/ARF: 35.29 (4.51--275.82)\                                                                              
                                                   Hospital LOS\                                                                                               
                                                   ARI/ARF: 101.5 ± 68.8 vs. 69.7 ± 48.5 days                                                                  

  Narciso et al. \[[@B60-jcm-08-00372]\]           Mortality\                                                                                                  None
                                                   Dialysis: 6.7 (3.49--12.96)                                                                                 

  Romano et al. \[[@B45-jcm-08-00372]\]            Hospital mortality\                                                                                         None
                                                   AKI: 1.88 (0.76--4.65)                                                                                      

  Leithead et al. \[[@B39-jcm-08-00372]\]          Mortality\                                                                                                  Age, sex, MELD score, eGFR, DM
                                                   1.71 (1.35--2.17)                                                                                           

  Klaus et al. \[[@B46-jcm-08-00372]\]             Mortality\                                                                                                  None
                                                   AKI: 5.11 (1.39--18.71)\                                                                                    
                                                   Dialysis:14.4 (4.60--45.09)                                                                                 

  Kim et al. \[[@B47-jcm-08-00372]\]               1-year mortality\                                                                                           None
                                                   Dialysis: 56.5 (12.32--259.20)                                                                              

  Karapanagiotou et al. \[[@B48-jcm-08-00372]\]    6-month mortality\                                                                                          Vasopressor use, RBC transfusion
                                                   RIFLE: 3.08 (1.09--1.95)\                                                                                   
                                                   AKIN: 9.34 (1.20--15.69)\                                                                                   
                                                   ICU LOS\                                                                                                    
                                                   RIFLE: 15.44 ± 15.41 vs. 8.65 ± 12.59 days\                                                                 
                                                   AKIN: 13.75 ± 14.53 vs. 9.1 ± 13.08 days                                                                    

  Nadeem et al. \[[@B49-jcm-08-00372]\]            ICU LOS\                                                                                                    N/A
                                                   AKI: 13.4 ± 19 vs. 5.5 ± 4.7 days                                                                           

  Kirnap et al. \[[@B61-jcm-08-00372]\]            Mortality\                                                                                                  None
                                                   AKI: 1.85 (0.65--5.23)\                                                                                     
                                                   ICU LOS\                                                                                                    
                                                   AKI: 10 ± 8 vs. 3 ± 2 days\                                                                                 
                                                   Hospital LOS\                                                                                               
                                                   AKI: 26 ± 70 vs. 16 ± 7 days                                                                                

  Barreto et al. \[[@B63-jcm-08-00372]\]           Hospital mortality\                                                                                         None
                                                   AKIN stage 2 or 3: 4.3 (1.3--14.6)                                                                          

  Hilmi et al. \[[@B19-jcm-08-00372]\]             30-day mortality\                                                                                           None
                                                   AKI: 3/221(1.4%) vs. 0/203 (0%)\                                                                            
                                                   CKD\                                                                                                        
                                                   AKI: 1.69 (1.11--2.58)                                                                                      

  Park et al. \[[@B64-jcm-08-00372]\]              Hospital mortality\                                                                                         None
                                                   3.44 (1.89--6.25)\                                                                                          
                                                   1-year mortality\                                                                                           
                                                   AKI: 1.57 (0.95--2.58)\                                                                                     
                                                   ICU LOS\                                                                                                    
                                                   6 (6--7) in no AKI vs. 6 (6--9) in Risk vs. 7 (6--18) in Injury vs. 11 (10--85) in Failure group\           
                                                   Hospital LOS\                                                                                               
                                                   29 (23--42) in no AKI vs. 31 (21--43) in Risk vs. 33 (26--47) in Injury vs. 46 (16--108) in Failure group   

  Mukhtar et al. \[[@B65-jcm-08-00372]\]           Mortality\                                                                                                  Graft weight to recipient body weight ratio, baseline creatinine, MELD score, DM, Terlipressin use, massive transfusion, vasopressor use
                                                   AKI: 2.1 (1.18--4.0)                                                                                        

  Sang et al. \[[@B66-jcm-08-00372]\]              Mortality\                                                                                                  None
                                                   RIFLE AKI: 2.29 (1.29--4.05)\                                                                               
                                                   AKIN AKI: 1.69 (1.06--2.67)                                                                                 

  Wyssusek et al. \[[@B67-jcm-08-00372]\]          Mortality\                                                                                                  None
                                                   AKI: 3.23 (0.43--24.27)                                                                                     

  Jun et al. \[[@B70-jcm-08-00372]\]               Mortality\                                                                                                  ABO incompatibility, MELD score, hypertension, coronary artery disease, age, post-reperfusion syndrome, vasopressor, crystalloid, RBC transfusion, FFP transfusion, operation time, cold ischemic time
                                                   AKI: 0.36 (0.09--1.43)                                                                                      

  Inoue et al. \[[@B71-jcm-08-00372]\]             1-year mortality\                                                                                           None
                                                   AKI: 4.54 (1.27--16.32)\                                                                                    
                                                   CKD\                                                                                                        
                                                   AKI: 2.33 (0.66--8.29)                                                                                      

  Mizota et al. \[[@B74-jcm-08-00372]\]            Hospital mortality\                                                                                         Age, MELD score, blood type incompatibility, re-transplantation
                                                   AKI: 2.53 (1.23--5.22)\                                                                                     
                                                   CKD\                                                                                                        
                                                   AKI: 2.46 (1.51--4.02)                                                                                      

  Erdost et al. \[[@B72-jcm-08-00372]\]            30-day mortality\                                                                                           None
                                                   RIFLE AKI: 4.15 (1.72--10.00)\                                                                              
                                                   AKIN AKI: 440.83 (58.24--3336.87)\                                                                          
                                                   KDIGO AKI: 35/64 (55%) vs. 0/376                                                                            

  Chae et al. \[[@B75-jcm-08-00372]\]              Hospital mortality\                                                                                         None
                                                   AKI: 1.63 (0.73--3.60)\                                                                                     
                                                   ICU LOS\                                                                                                    
                                                   AKI: 7 (6--8) vs. 7 (5--7) days\                                                                            
                                                   Hospital LOS\                                                                                               
                                                   AKI: 28 (22--39) vs. 23 (21--31) days                                                                       

  Mizota et al. \[[@B76-jcm-08-00372]\]            Hospital mortality\                                                                                         None
                                                   Severe AKI: 3.56 (1.78--7.09)                                                                               

  Trinh et al. \[[@B77-jcm-08-00372]\]             Mortality\                                                                                                  Age, sex, MELD score, baseline eGFR, ATG induction, pretransplant hypertension and DM
                                                   AKI: 1.41 (1.03--1.92)\                                                                                     
                                                   CKD stage 4--5\                                                                                             
                                                   AKI: 2.39 (1.27--4.47)                                                                                      

  Kalisvaart et al. \[[@B78-jcm-08-00372]\]        Hospital mortality\                                                                                         None
                                                   AKI: 7.96 (1.66--38.25)\                                                                                    
                                                   ICU LOS\                                                                                                    
                                                   AKI: 3 (2--5) vs. 2 (2--3) days\                                                                            
                                                   Hospital LOS\                                                                                               
                                                   AKI: 24 (19--35) vs. 17 (14--27) days                                                                       

  Nadkarni et al. \[[@B16-jcm-08-00372]\]          Hospital mortality\                                                                                         Not specified
                                                   Dialysis: 2.00 (1.55--2.59)                                                                                 

  Chen et al. \[[@B79-jcm-08-00372]\]              30-day mortality\                                                                                           ALP, MELD score, operation time, blood transfusion
                                                   AKI: 4.05 (1.02--16.18)                                                                                     

  Zongyi et al. \[[@B35-jcm-08-00372]\]            1-year mortality\                                                                                           None
                                                   RIFLE failure stage AKI: 12.25 (8.99--16.70)\                                                               
                                                   1-year graft failure\                                                                                       
                                                   RIFLE failure stage AKI: 11.73 (8.57--16.06)\                                                               
                                                   Hospital LOS\                                                                                               
                                                   RIFLE failure stage AKI: 16 (6--34.5) vs. 25 (18--35) days                                                  

  Zhou et al. \[[@B30-jcm-08-00372]\]              14-day mortality\                                                                                           None
                                                   AKI: 3.35 (0.94--11.98)\                                                                                    
                                                   Hospital LOS\                                                                                               
                                                   AKI: 28.13 ± 20.04 vs. 26.16 ± 11.91 days                                                                   

  Jochmans et al. \[[@B29-jcm-08-00372]\]          1-year mortality\                                                                                           None
                                                   AKI: 6.11 (0.52--71.16)\                                                                                    
                                                   1-year graft failure\                                                                                       
                                                   AKI: 2.54 (0.61--10.55)\                                                                                    
                                                   CKD\                                                                                                        
                                                   AKI:1.17 (0.40--3.44)\                                                                                      
                                                   ICU LOS\                                                                                                    
                                                   AKI: 4 (3--9) vs. 2 (2--4)\                                                                                 
                                                   Hospital LOS\                                                                                               
                                                   AKI: 23 (17--46) vs. 16 (13--26)                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations:: ABO incompatibility, incompatibility of the ABO blood group; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ALP, alkaline phosphatase; APACHE, Acute Physiology and Chronic Health Evaluation; ARI, acute renal injury; ARF, acute renal failure; AST, aspartate aminotransferase; ATG, Anti-thymocyte globulin; BMI, body mass index; BUN, blood urea nitrogen; CMV, cytomegalovirus; DCD, donation after circulatory death; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FFP, fresh frozen plasma; HCV, hepatitis C virus; HES, hydroxyethyl starch; ICU, intensive care unit; KDIGO, Kidney Disease Improving Global Outcomes; SCr, serum creatinine; MAP, mean arterial pressure; MELD, Model For End-Stage Liver Disease; MMF, mycophenolate mofetil; N/A, not available; NGAL, neutrophil gelatinase-associated lipocalin; PBC, primary biliary cirrhosis; RBC, red blood cell; RRT, renal replacement therapy; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; SOFA, Sequential Organ Failure Assessment; SvO2, mixed venous oxygen saturation.
